BioWorld

Feb. 9, 2006

Entereg’s Positive Phase III Data Drive Up Adolor’s Stock

Adolor Corp. unveiled positive Phase III data on Entereg (alvimopan), its partnered product for postoperative ileus, boosting shares in the company. (BioWorld Today) Read More

Immtech Prices $16M Public Offering; EpiCept Adds $11M

PDZ Binding Domain Origins Determinant Of Flu Severity

Optimized Proteases Garner $30M In Catalyst’s Series B

Oscient Gets Ramoplanin Rights Back From Pfizer

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 19, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 19, 2025.

Apollo’s APL-4098 shows potent antileukemic effects

BioWorld Science

Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...

ASH 2025: Ianalumab data offer break from chronic ITP therapy

BioWorld

Novartis AG’s monoclonal antibody, ianalumab (VAY-736), when added to standard-of-care eltrombopag, extended disease control of primary immune thrombocytopenia...